公开(公告)号：US09469689B2

公开(公告)日：2016-10-18

申请号：US14798849

申请日：2015-07-14

Applicant: AbbVie Inc.

Inventor： Ming-Jiu Chen ,  Chung-Ming Hsieh ,  Jijie Gu ,  Susan E. Morgan-Lappe ,  Yingchun Li

IPC: C07K16/00 ,  C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61K39/00

CPC classification number: C07K16/28 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.

公开(公告)号：US20200255508A1

公开(公告)日：2020-08-13

申请号：US16576078

申请日：2019-09-19

Applicant: AbbVie Inc.

Inventor： Lorenzo Benatuil ,  Erwin R. Boghaert ,  Jijie Gu ,  Maria Harris ,  Jonathan A. Hickson ,  Chung-Ming Hsieh ,  Yuliya Kutskova ,  Yingchun Li ,  Zhihong Liu ,  Susan Morgan-Lappe

IPC: C07K16/22 ,  C07K7/08 ,  C07K7/06 ,  A61K45/06 ,  A61K39/395 ,  C07K16/18 ,  C07K14/47

Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.

公开(公告)号：US09856319B2

公开(公告)日：2018-01-02

申请号：US14141503

申请日：2013-12-27

Applicant: AbbVie, Inc.

Inventor： Tariq Ghayur ,  Jijie Gu

IPC: C07K16/00 ,  C07K16/28 ,  C07K16/32 ,  C07K16/46

CPC classification number: C07K16/2809 ,  C07K16/2863 ,  C07K16/2878 ,  C07K16/32 ,  C07K16/468 ,  C07K2317/35 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: Engineered monovalent binding proteins that bind to one or more ligands (such as an antigen) via one binding domain are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.

公开(公告)号：US20160175316A1

公开(公告)日：2016-06-23

申请号：US14972983

申请日：2015-12-17

Applicant: AbbVie Inc.

Inventor： Philip Bardwell ,  Tariq Ghayur ,  Jijie Gu ,  Ingela Beatrice Vikstrom ,  Andrew Mark Lew ,  David Matthew Tarlinton ,  Emma Margarele Carrington ,  David Ching Siang Huang

IPC: A61K31/5377 ,  A61K38/13

CPC classification number: A61K31/5377 ,  A61K31/44 ,  A61K31/497 ,  A61K38/13

Abstract: Methods of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection are disclosed.

Abstract translation: 公开了预防或治疗器官，造血干细胞或骨髓移植排斥的方法。

公开(公告)号：US20140308286A1

公开(公告)日：2014-10-16

申请号：US14219511

申请日：2014-03-19

Applicant: AbbVie Inc.

Inventor： Tariq Ghayur ,  Jochen G. Salfeld ,  Michael J. McPherson ,  Maria C. Harris ,  Junjian Liu ,  Peter C. Isakson ,  Jijie Gu

IPC: C07K16/24 ,  C07K16/44 ,  C07K16/22

CPC classification number: C07K16/241 ,  C07K16/22 ,  C07K16/2803 ,  C07K16/2875 ,  C07K16/44 ,  C07K16/468 ,  C07K2317/31 ,  C07K2317/73

Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

Abstract translation: 本发明涉及工程化的多价和多特异性结合蛋白，制备方法，具体涉及用于预防，诊断和/或治疗疾病的用途。

公开(公告)号：US20140186377A1

公开(公告)日：2014-07-03

申请号：US14090664

申请日：2013-11-26

Applicant: AbbVie, Inc.

Inventor： Jijie Gu ,  Charles W. Hutchins ,  Rong-Rong Zhu ,  Jianwei Shen ,  Maria C. Harris ,  Eileen Belanger ,  Tariq Ghayur ,  Paul R. Hinton ,  Veronica M. Juan ,  John Mankovich ,  Junjian Liu

IPC: C07K16/18 ,  A61K31/573 ,  A61K31/405 ,  A61K39/395

CPC classification number: C07K16/18 ,  A61K31/405 ,  A61K31/573 ,  A61K39/39533 ,  A61K2039/505 ,  C07K16/26 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  Y02A50/386 ,  Y02A50/401 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/478 ,  Y02A50/481

Abstract: The present invention encompasses prostaglandin E2 (PGE2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E2 and neutralize prostaglandin E2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E2 and for inhibiting prostaglandin E2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E2 activity is detrimental.

Abstract translation: 本发明包括前列腺素E2（PGE2）结合蛋白。 本发明涉及野生型，嵌合型，CDR移植和人源化的抗体。 优选的抗体对前列腺素E2具有高亲和力，并在体外和体内中和前列腺素E2活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗原结合部分可用于检测前列腺素E2和用于抑制前列腺素E2活性，例如在患有前列腺素E2活性有害的病症的人类受试者中。

公开(公告)号：US20180194861A1

公开(公告)日：2018-07-12

申请号：US15742331

申请日：2016-07-08

Applicant: AbbVie Inc.

Inventor： Feng Dong ,  Jijie Gu ,  Tariq Ghayur

IPC: C07K16/46

CPC classification number: C07K16/468 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/64 ,  C07K2319/00 ,  C07K2319/30

Abstract: Engineered binding proteins comprising a modified constant region, such as an IgG constant region modified to contain a CH2 domain from an IgM, a CH2 domain from an IgE, or a variant thereof, are disclosed. The binding proteins can be multispecific, including bi-, tri-, and tetra-specific constructs. Also disclosed are uses of the binding proteins in the diagnosis, prevention, and/or treatment of disease.

公开(公告)号：US20160319026A1

公开(公告)日：2016-11-03

申请号：US15091468

申请日：2016-04-05

Applicant: AbbVie Inc.

Inventor： Tariq Ghayur ,  Junjian Liu ,  Gillian A. Kingsbury ,  Edward B. Reilly ,  Susan E. Morgan-Lappe ,  Jijie Gu

IPC: C07K16/28 ,  G01N33/74 ,  A61K39/395 ,  A61K47/48 ,  A61K45/06

CPC classification number: C07K16/2863 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/6879 ,  A61K2039/505 ,  C07K16/22 ,  C07K16/28 ,  C07K16/2809 ,  C07K16/40 ,  C07K16/468 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00 ,  G01N33/74 ,  G01N2333/71 ,  Y02A50/386 ,  Y02A50/41 ,  Y02A50/412

Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

公开(公告)号：US20160280791A1

公开(公告)日：2016-09-29

申请号：US15075630

申请日：2016-03-21

Applicant: AbbVie Inc.

Inventor： Tariq Ghayur ,  Jijie Gu ,  Carrie L. Goodreau

IPC: C07K16/28 ,  A61K45/06 ,  C07K16/46 ,  A61K39/395 ,  C07K16/32 ,  C07K16/30

CPC classification number: C07K16/2863 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/30 ,  C07K16/32 ,  C07K16/468 ,  C07K2317/14 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/565 ,  C07K2317/64 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: Engineered multivalent and multispecific binding proteins that bind two different (e.g., nonoverlapping) epitopes of the same receptor or two different receptors expressed on the same cell are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.

公开(公告)号：US09394363B2

公开(公告)日：2016-07-19

申请号：US13685899

申请日：2012-11-27

Applicant: ABBVIE DEUTSCHLAND GMBH & CO. KG ,  ABBVIE INC.

Inventor： Jijie Gu ,  Chung-Ming Hsieh ,  Zhen Wu ,  Enrico L. DiGiammarino ,  Feng Luo ,  Gerard B. Fox ,  John E. Harlan ,  Martin Schmidt ,  Ralf Loebbert ,  Reinhold Mueller ,  Ulrich Ebert ,  Volker Nimmrich

IPC: C07K16/28 ,  A61K39/395 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/464 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  C12P21/005 ,  Y02A50/466

Abstract: The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid β and advanced glycation-end-products.

Abstract translation: 本申请涉及分离的蛋白质，特别是单克隆抗体，特别是结合RAGE蛋白质的CDR-移植的人源化抗体。 具体地说，这些抗体具有抑制RAGE与其各种配体结合的能力。 本申请中描述的抗体或其部分可用于治疗由RAGE的病理生理学配体表征或诱导的疾病或病症，例如错折叠蛋白如淀粉样蛋白和bgr; 和晚期糖基化终产物。